THE LONG AWAITED TAME TRIAL RESULTS ARE IN!
The TAME trial, a phase III clinical trial, aimed to investigate whether targeted therapeutic mild hypercapnia (TTMH) could improve neurological outcomes at 6 months for resuscitated cardiac arrest patients in comparison to standard care (targeted normocapnia). This study holds significant importance in exploring potential advancements in post-cardiac arrest treatment strategies.
REMAP-CAP’S NEW TRIAL DEVELOPMENTS
The world of REMAP-CAP is constantly evolving, here’s what’s new!
REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.
REMAP-CAP: NEW RESULTS FROM THE ACE2 RAS DOMAIN!
New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.
Better Health Outcomes Together - The PANORAMIC Case Study with Lead Statistician Ly-Mee Yu
Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.
ASCOT Trial Results are in!
New results are in for the ASCOT Trial (Australasian Covid-19 Trial), another study in Spiral’s manifest of platform trials. This platform trial was set up to evaluate 3 different treatment approaches for effectiveness against COVID-19. Each of these approaches is called a 'domain'. The findings from the anticoagulation domain have recently been published in the New England Journal of Medicine Evidence.
ACTA Insights with Audrey
After two years of online meetings, attending the Australian Clinical Trials Alliance Annual Science meeting in Adelaide in November felt fantastic. It was a whirlwind of activity, new technology, connections, learning, and, importantly, an excellent opportunity to connect with industry peers.
Case Study - SNAP Trial with Professor Steven Tong
As clinical trials in the world grow and develop, so too do the opportunities for Spiral to make a difference with our savvy platform software.
We speak to Professor Steven Tong about the SNAP Trial, his experience working with the team at Spiral, and the application and impact of our Spinnaker software in his study.